Evidence map›Paper›PMID 24661998›Full record

ArticleThe international journal of biochemistry & cell biology2014

Blocking interaction of viral gp120 and CD4-expressing T cells by single-stranded DNA aptamers.

Nianxi Zhao, Sung-nan Pei, Parag Parekh, Eric Salazar, Youli Zu

Abstract read
In one paragraph

Article in The international journal of biochemistry & cell biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Nianxi ZhaoDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital, and Cancer Pathology Laboratory, Houston Methodist Research Institute, 6565 Fannin Street, Houston, TX 77030, USA.
Sung-nan PeiDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital, and Cancer Pathology Laboratory, Houston Methodist Research Institute, 6565 Fannin Street, Houston, TX 77030, USA.
Parag ParekhDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital, and Cancer Pathology Laboratory, Houston Methodist Research Institute, 6565 Fannin Street, Houston, TX 77030, USA.
Eric SalazarDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital, and Cancer Pathology Laboratory, Houston Methodist Research Institute, 6565 Fannin Street, Houston, TX 77030, USA.
Youli ZuDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital, and Cancer Pathology Laboratory, Houston Methodist Research Institute, 6565 Fannin Street, Houston, TX 77030, USA. Electronic address: yzu@houstonmethodist.org.
Methodist Hospital · USMethodist Hospital · US

Funding

Tissue ResourceP50CA126752 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Leonid S Metelitsa · 2007 to 2026
$51.4M
A bifunctional nanomedicine for both specific imaging and targeting therapy of anR01CA151955 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI ZU, YOULI · 2010 to 2014
$1.5M
RFA-CA -12-003 - Activatable One-Drop and One-Step Assay for Circulating Tumor CeR33CA173382 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI ZU, YOULI · 2012 to 2014
$1.1M
NCI NIH HHS 5P50CA126752NCI NIH HHS P50 CA126752NCI NIH HHS R01 CA151955NCI NIH HHS R01CA151955NCI NIH HHS R33 CA173382NCI NIH HHS R33CA173382
6 · The paper itself

Abstract

To investigate the potential clinical application of aptamers to prevention of HIV infection, single-stranded DNA (ssDNA) aptamers specific for CD4 were developed using the systematic evolution of ligands by exponential enrichment approach and next generation sequencing. In contrast to RNA-based aptamers, the developed ssDNA aptamers were stable in human serum up to 12h. Cell binding assays revealed that the aptamers specifically targeted CD4-expressing cells with high binding affinity (Kd=1.59nM), a concentration within the range required for therapeutic application. Importantly, the aptamers selectively bound CD4 on human cells and disrupted the interaction of viral gp120 to CD4 receptors, which is a prerequisite step of HIV-1 infection. Functional studies showed that the aptamer polymers significantly blocked binding of viral gp120 to CD4-expressing cells by up to 70% inhibition. These findings provide a new approach to prevent HIV-1 transmission using oligonucleotide aptamers.

Indexed as

Aptamers, NucleotideCD4-Positive T-LymphocytesDNA, Single-StrandedHIV Envelope Protein gp120HIV InfectionsHumansSELEX Aptamer TechniqueAptamers, NucleotideDNA, Single-StrandedHIV Envelope Protein gp120gp120HIV infection preventionHybrid SELEXSpecific blockingssDNA CD4 aptamer

Identifiers

PMID24661998
PMCPMC4041034
OpenAlexW2057518975

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.